Mar 1, 2012 · Conclusion: Florbetapir F 18 appears to have a wide effective dose range and a high test–retest reliability for both quantitative (SUVr) values and visual assessment of the ligand.

Oct 4, 2022 · The present multicenter study suggested that 18 F-florbetapir PET can exert a considerable clinical impact on AD and non-AD diagnosis and on patient management, particularly …

It introduces criteria to determine whether an image is associated with an intermediate-to-high likelihood of pathologic AD or with having any identifiable cortical amyloid level above that seen in low-risk …

Jul 29, 2020 · Conclusion: Our study suggests that 18 F-FBB is a useful tracer for the evaluation of amyloid-β deposition in vivo and that global SUVR of 18 F-FBB PET might be a reliable tool in the …

Purpose Florbetapir (AV-45) has been shown to be a reliable tool for assessing in vivo amyloid load in patients with Alzheimer's disease from the early stages. However, nonspecific white matter binding …

Mar 13, 2025 · trajectories modeled separately for FBB and FBP. While slopes differ by approximately 1 CL/year between tracers, given that A+ individuals accumulate amyloid at a rate of 5 CL/year, this …

The higher amyloid burden in the aMCI patients suggests that these patients may also be more likely to develop Alzheimer’s disease than other patients diagnosed with major depression.

Jan 18, 2012 · In the present study, our aim was to assess the feasibility of using PET imaging with florbetapir in third-level clinical settings to differentiate patients with mild to moderate AD or MCI …

Mar 27, 2021 · This study aims to characterize the population with earliest abnormal Aβ accumulation using 18 F-florbetaben PET. Quantitative thresholds for the early (SUVR early) and established …

Aug 1, 2011 · Results: When compared with the other groups, AD patients demonstrated significantly higher SUVRs ( P < 0.0001) in neocortical areas. Most AD patients (96%) and 60% of MCI subjects …